Edemede a ga-enyere gị aka ịhọrọ nke kachasị gị mma site n'ịza ajụjụ ndị a:
1. Kedu ihe dị iche n'etiti tirzepatide na retatrutide?
2.Gịnị bụ uru nke tirzepatide?
3.Gịnị bụ uru nke retatrutide?
4.Tụnyere Uru Retatrutide na Tirzepatide
Kedu ihe dị iche n'etiti retatrutide na tirzepatide?
Isi ihe dị iche n'etiti tirzepatide na retatrutide dị na nhazi ha.Tirzepatide bụ ngwakọta nke ihe atọ na-arụ ọrụ - liraglutide, glucagon-dị ka peptide-1 agonist (GLP-1);analog nke oxyntomodulin;yana GLP-2 analogue.Retarutide, n'aka nke ọzọ, mejupụtara otu ihe na-arụ ọrụ - exenatide, GLP-1 ọzọ egosipụtara na pancreas.A na-eji ọgwụ abụọ ahụ ejikwa ụdị ọrịa shuga 2 site n'ịba ụba mmepụta insulin na ibelata ọkwa glucose ọbara.Otú ọ dị, egosiwokwa retarutide iji belata agụụ nke ọma karịa tirzepatide naanị n'ihi mmetụta ya na hormones na-etinye aka na agụụ na satiety.Dị ka ndị dị otú a, enwere ike iji ya dị ka akụkụ nke usoro agbakwunyere maka njikwa ibu maka ndị nwere ọrịa shuga bụ ndị buru ibu ma ọ bụ buru ibu.
Gịnị bụ uru nke tirzepatide?
①Njikwa glycemic dị mma na ọkwa A1C, na-eduga n'ịdị mma n'ozuzu ya
Tirzepatide, glucagon-dị ka peptide 1 agonist nnabata na GLP-1/glucose na-adabere insulinotropic polypeptide (GIP) dual agonist, bụ nhọrọ ọgwụgwọ ọhụrụ maka ụdị ọrịa shuga 2.Achọpụtala na ọ dị irè karịa retatrutide n'ịkwalite njikwa glycemic na ọkwa A1C.N'ime ule ụlọ ọgwụ, a na-ejikọta tirzepatide na mbelata dị ukwuu na ọkwa A1C na izu 12 ma e jiri ya tụnyere retatrutide (-2.3% vs -1.8%), na-eduga n'inwe ahụike zuru oke maka ndị ọrịa.
②Mbelata ihe ize ndụ nke ihe omume obi dị ka nkụchi obi na ọrịa strok
Tirzepatide na-enye ọtụtụ uru dị ukwuu maka ndị mmadụ nọ n'ihe ize ndụ maka ihe omume obi dị ka nkụchi obi na ọrịa strok.Nnyocha ọmụmụ 2019 nke e bipụtara na akwụkwọ akụkọ The Lancet chọpụtara na ndị mmadụ na-ewere tirzepatide nwere obere ihe ize ndụ nke nnukwu ọrịa obi (MACE) ma e jiri ya tụnyere ndị na-ewere retatrutide.Nke a gụnyere mbelata 35% na MACE ma e jiri ya tụnyere retatrutide, nke gosipụtara enweghị nnukwu ọdịiche dị na mmetụta na ihe egwu obi.N'ime ọmụmụ ihe ahụ, ndị nchọpụta ahụ chọpụtara na ndị ọrịa na-ewere tirzepatide nwere ahụmahụ dị ala nke ọrịa akwara obi, ọrịa myocardial infarction, nkụchi obi na ọrịa strok karịa ndị nọ na retatrutide.Na mgbakwunye, ndị sonyere na-ewere tirzepatide kọkwara ọkwa ọkwa shuga dị n'ọbara ka mma yana uru dị ntakịrị ma e jiri ya tụnyere ndị na-ewere retatrutide.N'ikpeazụ, ọ dị mkpa iburu n'obi na ndị mmadụ na-ewere tirzepatide abụghị naanị na echebewo MACE mana ha nwekwara mbelata na ọkwa HbA1c (ihe nrịbama maka mmebi ọrịa shuga ogologo oge) yana pasent abụba anụ ahụ ma e jiri ya tụnyere ọkwa ntọala.N'ikpeazụ, nsonaazụ ndị a na-arụtụ aka na ikike nke tirzepatide iji belata ihe omume obi na-ejikọta ya na ụdị ọrịa shuga 2 ma nyekwuo uru ndị metụtara nhazi ahụ.
Ibu ahụ dị ala ma e jiri ya tụnyere retatrutide, nke nwere ike inye aka belata ihe ize ndụ nke ọrịa ndị metụtara oke ibu
Tirzepatide nwere ọtụtụ uru ma e jiri ya tụnyere retatrutide, karịsịa ma a bịa n'ịdị arọ ahụ.Nnyocha achọpụtala na tirzepatide nwere ike ịkpata mbelata dị ukwuu na ịdị arọ ahụ karịa retatrutide n'ime ogologo oge.Enwere ike ịsị na nke a bụ ikike ya ịkwalite ọrụ nnabata GLP-1 ma kwalite satiety.Na mgbakwunye, a chọpụtala tirzepatide iji belata abụba afọ karịa retatrutide, nke nwere ike inye aka belata ihe ize ndụ nke ọrịa shuga, ọrịa obi, na ọrịa ndị ọzọ metụtara oke ibu.Ọzọkwa, egosila tirzepatide iji belata ọkwa shuga dị n'ọbara nke ọma karịa retatrutide.Mmetụta ndị a jikọtara ọnụ nwere ike melite nsonaazụ ahụike zuru oke metụtara oke ibu na arụ ọrụ metabolic.
③Mmụba ike ike n'ihi mmụba nke glucose metabolism
Otu n'ime uru bụ isi nke ị na-ewere tirzepatide bụ ikike ya ịbawanye ọkwa ume n'ihi mmụba nke glucose metabolism.Nke a bụ n'ihi na ndị na-anabata GLP1 agonists dị ka tirzepatide na-arụ ọrụ site n'ịkwalite ntọhapụ nke insulin na nzaghachi ọkwa shuga dị elu.Site n'ịba ụba mmepụta insulin na imeziwanye glucose metabolism, ahụ nwere ike iji glucose karịa maka mmanụ ọkụ na nke a nwere ike ime ka ike dịkwuo elu.Na mgbakwunye, GLP1 agonists ndị na-anabata ya nwekwara ike ibelata agụụ, na-eduga n'ịbelata agụụ nri na njikwa oke ibu.
Kedu uru retatrutide dị?
Retatrutidebụ ọgwụ injectable na-arụ ọrụ ogologo oge a na-eji agwọ ụdị ọrịa shuga nke abụọ.Ndị nchịkwa nri na ọgwụ ndị US (FDA) kwadoro ya maka ebumnuche a.Uru nke retatrutide dị ọtụtụ, na-eme ka ọ bụrụ nhọrọ mara mma n'etiti ọgwụ ndị ọzọ na-arịa ọrịa shuga.
Maka ndị mbido, retatrutide na-arụ ọrụ ngwa ngwa ozugbo etinyere ya ma nwee ike inwe mmetụta ya n'ime awa 24 nke nchịkwa.Nke a na-eme ka ọ na-eme ngwa ngwa karịa ọgwụ injectable ndị ọzọ na-eme ogologo oge dị ka tirzepatide, nke nwere ike were ihe dị ka izu ole na ole tupu a hụ mmetụta ọ bụla pụtara ìhè na ọkwa shuga dị n'ọbara.
Na mgbakwunye, ọmụmụ egosila na retatrutide dị irè n'ibelata ọkwa A1C na ndị nwere ụdị ọrịa shuga 2 mgbe ejiri ya na mgbanwe nri na mmega ahụ.Nnwale ụlọ ọgwụ egosila na retatrutide na-enyere aka belata ọkwa glucose na-ebu ọnụ yana njikwa glycemic zuru oke na ndị ọrụ ma e jiri ya tụnyere placebo.N'ọnọdụ ụfọdụ, ndị na-enwetaghị uru ọ bụla site na ọgwụ ọrịa shuga ọnụ arụpụtala ihe ịga nke ọma site na ọgwụgwọ retatrutide.
N'ikpeazụ, otu n'ime nnukwu uru nke retatrutide bụ usoro nchịkwa ya dị mfe;ọ na-achọ naanị otu injection kwa izu kama ịgbanye ọtụtụ ọgwụ kwa ụbọchị dịka ọtụtụ ọgwụgwọ ọrịa shuga ndị ọzọ.Nke a nwere ike ime ka ilekọta ọrịa shuga gị dịkwuo mfe ma nyere aka melite nrubeisi nke onye ọrịa na atụmatụ ọgwụgwọ ka oge na-aga.
Tụnyere Uru Retatrutide na Tirzepatide
Mgbe a bịara na nrụpụta ọrụ, egosila retatrutide iji belata ọkwa HbA1c site na 1.9-2.4%, ma e jiri ya tụnyere Tirzepatide nke na-ebelata ọkwa HbA1c site na 1.5-2%.Ọgwụ abụọ ahụ nwekwara mmetụta ndị yiri ya, dị ka ọgbụgbọ na isi ọwụwa.Otú ọ dị, ụfọdụ ndị nwere ike ịchọpụta na ha na-enweta mmetụta dị ole na ole na Retatrutide karịa na Tirzepatide n'ihi obere ihe achọrọ.
N'ihe gbasara nchekwa, A na-anabatakarị retarutide nke ọma mgbe ejiri ya na usoro akwadoro ma ọ naghị abawanye ohere nke hypoglycemia ma ọ bụ na-ebute oke ibu dị ka ọgwụgwọ ọrịa shuga ndị ọzọ nwere ike.N'aka nke ọzọ, Tirzepatide na-ebu ihe ize ndụ dị elu nke mmeghachi omume saịtị ịgba ntụtụ n'ihi oke ya.Na mgbakwunye, ọ bụrụ na ewere ya na oke doses, ọ nwere ike ibute oke hypoglycemia na ibu ibu.
Na nchịkọta, ma retarutide na tirzepatide bụ nhọrọ dị irè maka ijikwa ụdị ọrịa shuga 2 mana otu nwere ike dabara adaba maka ụfọdụ ndị ọrịa dabere na mkpa ha.Retarutide na-enye arụmọrụ dị mma yana mmetụta dị ole na ole ma ọ dịkwa nchebe na usoro akwadoro;Otú ọ dị, Tirzepatide nwere ike inye mbelata dị ukwuu na ọkwa HbA1c mana ọ nwekwara ike ibute nnukwu nsogbu nke mmetụta dị njọ ma ọ bụrụ na ejighi ya nke ọma.N'ikpeazụ, ọ dị mkpa ka gị na dọkịta gị kparịta ụka iji kpebie ụdị ọgwụgwọ kachasị mma maka gị dabere na ọnọdụ gị kpọmkwem na ebumnuche ahụike gị.
Bido ọgwụgwọ tirzepatide na semaglutide na LianFu
Oge nzipu: Mar-18-2024